CNS Pharmaceuticals, Inc. Cash and Cash Equivalents
CNS Pharmaceuticals, Inc. (CNSP) had Cash and Cash Equivalents of $19.98 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-12
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $19.98M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $2.95M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $7.20M; Cash and Cash Equivalents, at Carrying Value as first filed $7.20M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $9.86M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $19.98M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $2.95M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $7.20M 10-Q · filed 2026-08-12 | $7.20M 10-K · filed 2026-03-31 |
| 2025-09-30 | $9.86M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $12.13M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $13.05M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $6.46M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $6.97M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $1.49M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $815.23K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $548.72K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $909.55K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $4.28M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $5.11M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $10.06M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $7.03M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $8.96M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $12.44M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $5.00M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $8.33M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $6.89M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $11.08M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $14.04M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $1.31M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $2.63M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $5.38M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $7.24M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $630.11K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $911.93K 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $155.02K 10-Q · filed 2020-05-15 | |
| 2018-12-31 | $282.74K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |